Associated Banc Corp Has $204,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Associated Banc Corp reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,367 shares of the company’s stock after selling 203 shares during the period. Associated Banc Corp’s holdings in Novo Nordisk A/S were worth $204,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Novo Nordisk A/S in the 4th quarter worth approximately $404,910,000. Sustainable Growth Advisers LP increased its position in Novo Nordisk A/S by 23.6% during the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock worth $459,416,000 after acquiring an additional 1,021,498 shares during the period. Amundi raised its stake in Novo Nordisk A/S by 26.4% during the 4th quarter. Amundi now owns 3,311,456 shares of the company’s stock valued at $283,615,000 after purchasing an additional 692,567 shares during the last quarter. Parnassus Investments LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $51,072,000. Finally, DAVENPORT & Co LLC increased its holdings in shares of Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.8 %

Shares of NYSE:NVO opened at $77.22 on Monday. The company’s fifty day moving average is $83.95 and its 200-day moving average is $102.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15. The company has a market capitalization of $346.54 billion, a PE ratio of 23.47, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.